Anthera Pharmaceuticals, Inc.

Equities

ANTH

US03674U3005

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:50:58 2024-04-24 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-98.51%

2018	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	CI
2018	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	CI

Anthera Pharmaceuticals Announces Appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer

January 07, 2015 at 03:45 pm EST

Anthera Pharmaceuticals, Inc. announced the appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer. Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014.

Latest news about Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	18-07-02	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	18-06-27	CI
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura	18-03-12	CI
Transcript : Anthera Pharmaceuticals, Inc. - Special Call	18-03-12
Anthera Mulls Acquisitions	18-03-06	CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-05	CI
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura	18-02-05	CI
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors	18-01-08	CI
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing	18-01-03	CI
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura	17-12-11	CI
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura	17-11-09	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-06	CI
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors	17-10-22	CI
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod	17-08-28	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-09	CI
Anthera Pharmaceuticals, Inc. Announces Executive Changes	17-07-14	CI
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura	17-07-06	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index	17-06-23	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index	17-06-23	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index	17-06-23	CI
Anthera Pharmaceuticals Announces Resignation of Klara Dickinson-Eason as Senior Vice President, Chief Regulatory Officer, Effective June 20, 2017	17-06-19	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from S&P Global BMI Index	17-06-19	CI
Certain Common Stock of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	17-06-11	CI
Certain Options of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	17-06-11	CI
Certain Warrants of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	17-06-11	CI

Chart Anthera Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANTHERA PHARMACEUTICALS, INC.	-98.51%	26
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs